Director in Cardiovascular and Renal ResearchRegeneron Pharmaceuticals, Inc.Tarrytown, New York, United States
PB0134 - A novel method for measuring ex vivo intrinsic pathway-triggered thrombin generation in the development of REGN9933, a monoclonal antibody targeting factor XI
Sunday, June 23, 202413:45 – 14:45 ICT
PB0384 - Antibodies against factor XI/factor XIa effectively anticoagulate without increasing bleeding risk in cynomolgus monkeys
PB0235 - Trial-in-progress: A two-part open-label study of an in vivo CRISPR/Cas9-based coagulation factor IX targeted gene insertion therapy (REGV131-LNP1265), in participants with hemophilia B (BEYOND-9)
